November 18, 2024 02:55 PM ESTUpdated 03:33 PM
R&D
Cell/Gene Tx

Neu­ro­gene pa­tient had life-threat­en­ing side ef­fect in Rett syn­drome study

Jared Whitlock

Features Editor

Neu­ro­gene has re­leased de­tails of an ad­verse event in a clin­i­cal tri­al test­ing its gene ther­a­py for Rett syn­drome, af­ter news of the safe­ty is­sue …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times